Wells Fargo & Company Kronos Bio, Inc. Call Options Transaction History
Wells Fargo & Company
- $434 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding KRON
# of Institutions
56Shares Held
19.8MCall Options Held
9.3KPut Options Held
100-
Vida Ventures Advisors, LLC2.77MShares$2.65 Million3.24% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.05MShares$1.96 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.92MShares$1.85 Million0.0% of portfolio
-
Partners Capital Investment Group, LLP Boston, MA1.61MShares$1.55 Million0.03% of portfolio
-
Alphabet Inc. Mountain View, CA1.44MShares$1.38 Million0.1% of portfolio
About Kronos Bio, Inc.
- Ticker KRON
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,769,100
- Market Cap $54.5M
- Description
- Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally...